Recombinant antibacterial group iia phospholipase a2 and methods of use thereof
AssigneeNew York University
InventorsJerrold Weiss, Peter Elsbach, Ning Sheng Liang
Life of this patent
Estimating the term…
Abstract
Disclose herein is a novel recombinant mutant protein of human Group IIA phospholipase A2 (PLA2) which has enhanced antibacterial activity when compared to the wild-type human Group IIA PLA2, pharmaceutical formulations comprising the protein and methods of use thereof. Additionally, the formulations may comprise other bioactive compounds, such as, e.g., conventional antibiotics, that act additively or synergistically with Group IIA PLA2 in order to promote bacterial killing.
Claims13
A method for killing Gram-positive bacteria in a human patient which comprises contacting said bacteria with a bactericidal-effective amount of mutant human Group IIA PLA2.
A method for killing Staphylococcus aureus bacteria which comprises contacting said bacteria with a bactericidal-effective amount of mutant Group IIA PLA2.
A method for treating a Staphylococcus aureus infection in a human which comprises administering to said human an amount effective for treating said infection of mutant human Group IIA PLA2.
A pharmaceutical formulation comprising mutant human Group IIA PLA2 and a pharmaceutically acceptable carrier or diluent, said formulation having bactericidal activity against Gram-positive bacteria.
A purified, isolated nucleic acid comprising the sequence as set forth in SEQ. ID No. 1.
A purified, isolated protein comprising the amino acid sequence as set forth in SEQ. ID No. 2.
A method for treating a human patient suffering from an infection caused by a Gram-positive bacteria comprising administering to a human in need of such treatment:
- (a) mutant human Group II PLA2;
- and
- (b) an antibiotic, the amounts of (a) and (b) together being effective to treat said infection.
Dependencies are inferred from the claim text.